Open Access Open Access  Restricted Access Subscription or Fee Access

A review of the evidence to explain pharmacological basis of injection (ab)use of buprenorphine–naloxone tablets

Tamoud Modak, MD, DM, Siddharth Sarkar, MD, MRCPsych, Yatan Pal Singh Balhara, MD

Abstract


Opioid use disorder is a major public health problem, and opioid replacement therapy with buprenorphine (BPN) is a clinically effective and evidence-based treatment for it. To deter misuse of the tablet through the injecting route, BPN coformulated with naloxone (BNX) in 4:1 ratio is available in many countries. Despite this, significant diversion and injecting use of the BNX combination has been reported from across the world. In this article, the pharmacological properties of BPN and BNX and the evidence for their diversion are reviewed. Also, a critical examination is made of the evidence supporting the role of naloxone in reducing the agonist effects of BPN when used through the injecting route. Based on this evidence, a hypothesis explaining the continued diversion of BNX has been proposed.


Keywords


buprenorphine–naloxone diversion, injection

Full Text:

PDF

References


Degenhardt L, Whiteford HA, Ferrari AJ, et al.: Global burden of disease attributable to illicit drug use and dependence: Findings from the global burden of disease study 2010. The Lancet. 2013; 382(9904): 1564-1574. DOI: 10.1016/S0140-6736(13)61530-5.

UNODC: World drug report. 2020. Available at https://wdr.unodc.org/wdr2020/index.html. Accessed November 26, 2020.

Degenhardt L, Charlson F, Ferrari A, et al.: The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet Psychiatry. 2018; 5(12): 987-1012.

Degenhardt L, Peacock A, Colledge S, et al.: Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. Lancet Glob Health. 2017; 5(12): e1192-e1207. DOI: 10.1016/S2214-109X(17)30375-3.

Nelson PK, Mathers BM, Cowie B, et al.: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. The Lancet. 2011; 378(9791): 571-583. DOI: 10.1016/S0140-6736(11)61097-0.

Sullivan LE, Fiellin DA: Narrative review: Buprenorphine for opioid-dependent patients in office practice. Ann Intern Med. 2008; 148(9): 662-670.

Mendelson J, Jones RT: Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment? Drug Alcohol Depend. 2003; 70(2 Suppl.): S29-S37. DOI: 10.1016/s0376-8716(03)00057-7.

Ling W: Buprenorphine for opioid dependence. Expert Rev Neurother. 2009; 9(5): 609-616. DOI: 10.1586/ern.09.26.

Larance B, Degenhardt L, Lintzeris N, et al.: Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. Drug Alcohol Depend. 2011; 118(2-3): 265-273.

Vicknasingam B, Mazlan M, Schottenfeld R, et al.: Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend. 2010; 111(1-2): 44-49.

Yokell MA, Zaller ND, Green TC, et al.: Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Curr Drug Abuse Rev. 2011; 4(1): 28-41. DOI: 10.2174/1874473711104010028

Handford C, Kahan M, Srivastava A, et al.: Buprenorphine/naloxone for opioid dependence: Clinical practice guideline. Available at http://cpsa.ca/wp-content/uploads/2015/07/buprenorphine_naloxone_CAMH2012.pdf?x91570. Accessed November 26, 2020.

Bruce RD, Govindasamy S, Sylla L, et al.: Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse. 2009; 35(2): 68-72.

Larance B, Lintzeris N, Ali R, et al.: The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend. 2014; 136: 21-27.

Dum JE, Herz A: In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol. 1981; 74(3): 627-633.

Hambrook J, Ranee MJ: The interaction of buprenorphine with the opiate receptor: Lipophilicity as a determining factor in drug-receptor kinetics; in Opiates and Endogenous Opioid Peptides (ed. Kosterlitz HW). Amsterdam: Elsevier. 1976.

Leander JD: Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology. 1987; 26(9): 1445-1447.

Negus SS, Picker MJ, Dykstra LA: Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats. Psychopharmacology (Berl.). 1989; 98(1): 141-143.

Walsh SL, Preston KL, Bigelow GE, et al.: Acute administration of buprenorphine in humans: Partial agonist and blockade effects. J Pharmacol Exp Ther. 1995; 274(1): 361-372.

Cone EJ, Gorodetzky CW, Yousefnejad D, et al.: The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984; 12(5): 577-581.

Hasbrouck JD: The antagonism of morphine anesthesia by naloxone. Anesth Analg. 1971; 50(6): 954-959. DOI: 10.1213/00000539-197150060-00011.

Johnstone RE, Jobes DR, Kennell EM, et al.: Reversal of morphine anesthesia with naloxone. Anesthesiol J Am Soc Anesthesiol. 1974; 41(4): 361-367.

Fishman J, Roffwarg H, Hellman L: Disposition of naloxone- 7, 8-3H in normal and narcotic-dependent men. J Pharmacol Exp Ther. 1973; 187(3): 575-580.

Smith K, Hopp M, Mundin G, et al.: Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther. 2012; 50(5): 360-367.

Weinstein S, Pfeffer M, Schor J, et al.: Metabolites of naloxone in human urine. J Pharm Sci. 1971; 60(10): 1567-1568.

Berkowitz BA, Ngai S, Hempstead J, et al.: Disposition of naloxone: Use of a new radioimmunoassay. J Pharmacol Exp Ther. 1975; 195(3): 499-504.

Ngai S, Berkowitz BA, Yang J, et al.: Pharmacokinetics of naloxone in rats and in ManBasis for its potency and short duration of action. Anesthesiol J Am Soc Anesthesiol. 1976; 44(5): 398-401.

Fujimoto JM: Isolation of naloxone-3-glucuronide from human urine. Proc Soc Exp Biol Med. 1970; 133(1): 317-319.

Alho H, Sinclair D, Vuori E, et al.: Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007; 88(1): 75-78. DOI: 10.1016/j.drugalcdep.2006.09.012

Ho RCM, Chen KY, Broekman B, et al.: Buprenorphine prescription, misuse and service provision: A global perspective. Adv Psychiatr Treat. 2009; 15(5): 354-363.

Raffa R, Pergolizzi JV: A modern analgesics pain ‘pyramid’. J Clin Pharm Ther. 2014; 39(1): 4-6.

WHO: WHO | access to buprenorphine, methadone and oral morphine. 2020. Available at https://www.who.int/hiv/amds/controlmedicine/en/. Accessed November 26, 2020.

Dart R: Evaluation of ADFs using RADARS system data. In 5th Annual Scientific Meeting Presentation. Bethesda. MD. 2011.

Degenhardt L, Larance BK, Bell JR, et al.: Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Med J Aust. 2009; 191(3): 161-165.

Bazazi AR, Yokell M, Fu JJ, et al.: Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011; 5(3): 175-180. DOI: 10.1097/ADM.0b013e3182034e31.

Uosukainen H, Kauhanen J, Voutilainen S, et al.: Twelve-year trend in treatment seeking for buprenorphine abuse in Finland. Drug Alcohol Depend. 2013; 127(1-3): 207-214. DOI: 10.1016/j.drugalcdep.2012.07.002.

Simojoki K, Alho H: A five-year follow-up of buprenorphine abuse potential. J Alcohol Drug Depend. 2013; 2(1): 1000111. DOI: 10.4172/2329-6488.1000111.

Kelty E, Cumming C, Troeung L, et al.: Buprenorphine alone or with naloxone: Which is safer? J Psychopharmacol. 2018; 32(3): 344-352. DOI: 10.1177/0269881118756015.

Weinhold LL, Preston KL, Farre M, et al.: Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend. 1992; 30(3): 263-274.

Dowling J, Isbister GK, Kirkpatrick CMJ, et al.: Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008; 30(4): 490-496. DOI: 10.1097/FTD.0b013e3181816214.

Davis JL, Messenger KM, LaFEVERS DH, et al.: Pharmacokinetics of intravenous and intramuscular buprenorphine in the horse. J Vet Pharmacol Ther. 2012; 35(1): 52-58. DOI: 10.1111/j.1365-2885.2011.01284.x.

Mendelson J, Jones RT, Fernandez I, et al.: Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther. 1996; 60(1): 105-114.

Berkowitz BA: The relationship of pharmacokinetics to pharmacological activity: Morphine, methadone and naloxone. Clin Pharmacokinet. 1976; 1(3): 219-188.

Fudala PJ, Yu E, Macfadden W, et al.: Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend. 1998; 50(1): 1-8. DOI: 10.1016/S0376-8716(98)00008-8.

Mendelson J, Jones RT, Welm S, et al.: Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl.). 1999; 141(1): 37-46. DOI: 10.1007/s002130050804.

Jones JD, Manubay JM, Mogali S, et al.: Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. Drug Alcohol Depend. 2017; 179: 362-369. DOI: 10.1016/j.drugalcdep.2017.06.033.

Stoller KB, Bigelow GE, Walsh SL, et al.: Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl.). 2001; 154(3): 230-242. DOI: 10.1007/s002130000637.

Comer SD, Sullivan MA, Vosburg SK, et al.: Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010; 105(4): 709-718. DOI: 10.1111/j.1360-0443.2009.02843.x.

Duke AN, Correia CJ, Walsh SL, et al.: Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers. Psychopharmacology (Berl.). 2010; 211(3): 303-312. DOI: 10.1007/s00213-010-1898-4.

Comer SD, Collins ED: Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther. 2002; 303(2): 695-703. DOI: 10.1124/jpet.102.038141.

Middleton LS, Nuzzo PA, Lofwall MR, et al.: The pharmacodynamics and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011; 106(8): 1460-1473. DOI: 10.1111/j.1360-0443.2011.03424.x.

Patil V: Effect of intravenous naloxone in opioid dependent men on sublingual buprenorphine maintenance treatment. 2014. Master’s Thesis, All India Institute of Medical Sciences, New Delhi.

Dhagudu NK, Ambekar A, Agrawal A, et al.: Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects. Drug Alcohol Rev. 2020; 39: 595-603. DOI: 10.1111/dar.13057.

Chiang CN, Hawks RL: Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003; 70(2 Suppl.): S39-S47.

Heyman JS, Koslo RJ, Mosberg HI, et al.: Estimation of the affinity of naloxone at supraspinal and spinal opioid receptors in vivo: Studies with receptor selective agonists. Life Sci. 1986; 39(19): 1795-1803. DOI: 10.1016/0024-3205(86)90099-8.

Kuhlman JJ Jr, Lalani S, Magluilo J Jr, et al.: Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. 1996; 20(6): 369-378.

Mendelson J, Upton RA, Everhart ET, et al.: Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997; 37(1): 31-37.

Jones R, Mendelson J: Determination of buprenorphine mass balance. NIDA Contract N01DA-4–8306 Rep Pharmacokinet Pharmacodyn Stud Medicat Dev. 1997.

Walter DS, Inturrisi CE: Absorption, distribution, metabolism, and excretion of buprenorphine in animals and humans. In Buprenorphine Combat Drug Abuse Unique Opioid. New York: Wiley-Liss, 1995: 11335.

Heel RC, Brogden RN, Speight TM, et al.: Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs. 1979; 17(2): 81-110.

Skulberg AK, Tylleskar I, Nilsen T, et al.: Pharmacokinetics-and- dynamics of intramuscular and intranasal naloxone: An explorative study in healthy volunteers. Eur J Clin Pharmacol. 2018; 74(7): 873-883.

Chang Y, Moody DE: Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDPglucuronosyltransferases. Drug Metab Lett. 2009; 3(2): 101-107. DOI: 10.2174/187231209788654117.

Rouguieg K, Picard N, Sauvage F-L, et al.: Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010; 38(1): 40-45. DOI: 10.1124/dmd.109.029546.

Brown SM, Holtzman M, Kim T, et al.: Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiol J Am Soc Anesthesiol. 2011; 115(6): 1251-1260.

Busse D, Leandersson S, Amberntsson S, et al.: Industrial approach to determine the relative contribution of seven major UGT isoforms to hepatic glucuronidation. J Pharm Sci. 2020; 109(7): 2309-2320. DOI: 10.1016/j.xphs.2020.03.013.

Mistry M, Houston JB: Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab Dispos. 1987; 15(5): 710-717.

European Monitoring Centre for Drugs and Drug Addiction: Strategies to Prevent Diversion of Opioid Substitution Treatment Medications (Perspectives on Drugs). European Monitoring Centre for Drugs and Drug Addiction, 2016.

Neale J, Tompkins CNE, Strang J: Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences. Drug Alcohol Rev. 2019; 38(5): 510-518. DOI: 10.1111/dar.12939.




DOI: https://doi.org/10.5055/jom.2021.0651

Refbacks

  • There are currently no refbacks.